GlassScriptPhysician profile
Paul A Snyder
NPI 1063502730
$3,865.24
in general payments reported to CMS, 2019-2025
13 companies · $819 in 2025
The $819 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $328 · 2021: $212 · 2022: $700 · 2023: $700 · 2024: $689 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694 · Entertainment: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.37 |
| Entertainment | $513.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $923.21 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Paragon Crt |
| Alcon Vision LLC | $842.13 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Optos, INC. | $652.03 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $538.73 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $249.67 | 2024-2025 | Xdemvy |
| Maculogix, INC. | $182.35 | 2019-2020 | |
| Dompe US, INC. | $115.44 | 2025 | Oxervate |
| Glaukos Corporation | $101.92 | 2025 | Idosetr |
| Oyster Point Pharma, INC. | $80.05 | 2022 | |
| Sight Sciences, INC. | $72.18 | 2022 | |
| Bausch & Lomb Americas INC. | $66.53 | 2023 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.60 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.